Roche recognised as a leader for corporate action on climate change
Basel, 27 October 2016
Ongoing commitment to reduce greenhouse gas emissions reflects Roche's sustainability efforts
For the second consecutive year, Roche (SIX: RO, ROG; OTCQX: RHHBY) ranks among the global leading companies for its performance in response to climate change. CDP, the international not-for-profit organisation that seeks to drive sustainable economies, has awarded Roche a position on the “Climate A List” in recognition of its actions to reduce emissions and mitigate climate change in the past reporting year. In addition to this global recognition, Roche is also ascribed as country leader in Switzerland and sector leader for “Healthcare, Pharma and Biotech” within the DACH region (Germany, Austria and Switzerland).
Roche is one of only seven healthcare companies to be awarded a position on the global Climate A List, which consist of 193 companies, in all sectors, from the original 5,800 assessed by CDP against its scoring methodology.
“We are very proud of this recognition for environmental stewardship,” said Roche CEO Severin Schwan. “Our commitment and tradition to protect natural resources and to reduce our impact on the environment remains critical to our sustainability strategy.”
One example of Roche’s actions on climate change is the recently completed building 1 at Basel headquarters. Building 1 is a highly energy-efficient building. It is heated with waste heat and cooled with groundwater, while setting new energy performance standards with its façade design and LED lighting.
Another example of reducing greenhouse gas (GHG) emissions is regarding the use of halogenated substances for refrigeration and/or fire suppression where Roche managed to achieve a 89.8% reduction compared to 2002. The importance of this is paralleled by the agreement taken at the United Nations Environment Programme meeting in Kigali, Rwanda, in October 2016. Nearly 200 countries struck a landmark deal to reduce the emissions of hydrofluorocarbons (HFCs), in a move that could prevent up to 0.5 degrees Celsius of global warming by the end of this century.
CDP, formerly Carbon Disclosure Project, is an international, not-for-profit organization providing the only global system for companies and cities to measure, disclose, manage and share vital environmental information. CDP works on behalf of 827 institutional investors with assets of over USD 100 trillion, to motivate companies to disclose their impacts on the environment and natural resources and take action to reduce them. CDP now holds the largest collection globally of primary climate change, water and forest risk commodities information and puts these insights at the heart of strategic business, investment and policy decisions. For more information, please visit www.cdp.net.
Roche is a global pioneer in pharmaceuticals and diagnostics focused on advancing science to improve people’s lives.
Roche is the world’s largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and diseases of the central nervous system. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management. The combined strengths of pharmaceuticals and diagnostics under one roof have made Roche the leader in personalised healthcare – a strategy that aims to fit the right treatment to each patient in the best way possible.
Founded in 1896, Roche continues to search for better ways to prevent, diagnose and treat diseases and make a sustainable contribution to society. Twenty-nine medicines developed by Roche are included in the World Health Organization Model Lists of Essential Medicines, among them life-saving antibiotics, antimalarials and cancer medicines. Roche has been recognised as the Group Leader in sustainability within the Pharmaceuticals, Biotechnology & Life Sciences Industry eight years in a row by the Dow Jones Sustainability Indices.
The Roche Group, headquartered in Basel, Switzerland, is active in over 100 countries and in 2015 employed more than 91,700 people worldwide. In 2015, Roche invested CHF 9.3 billion in R&D and posted sales of CHF 48.1 billion. Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan. For more information, please visit www.roche.com.
All trademarks used or mentioned in this release are protected by law.